Cover Image
市場調查報告書

罕見疾病用醫藥品的全球市場的未來展望

Global Orphan Drugs Market Outlook 2020

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 349903
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
罕見疾病用醫藥品的全球市場的未來展望 Global Orphan Drugs Market Outlook 2020
出版日期: 2016年01月01日 內容資訊: 英文 64 Pages
簡介

罕見疾病用醫藥品 (孤兒藥) 別名「利基開發、製造贏家」,為了治療還沒找到滿足的治療方法的罕見疾病患者而。還沒有治療方法的罕見疾病的患者全球僅約4000∼5000人,不過,由於暢銷藥物的專利到期和與學名藥的競爭,製藥產業著手罕見疾病治療藥的開發。來自各國政府的支援也成為市場成長的原因之一。罕見疾病用醫藥品的全球市場,2020年預計達到1億8000萬美元的規模。

本報告提供全球罕見疾病用醫藥品 (孤兒藥) 的市場相關分析,市場整體結構促進、阻礙因素,整體市場及各類型、各地區、各用途趨勢預測,臨床實驗中的開發中產品的資訊,今後的產品開發、市場成長的方向性,主要企業簡介與產品概要等相關調查。

第1章 分析師的見解

第2章 分析方法

第3章 罕見疾病用醫藥品:概要

第4章 市場推動因素與課題

  • 推動市場要素
    • 醫療費用支出的增加
    • 慢性疾病的患病人數的增加
    • 開發期間的縮短和ODE (罕見疾病用醫藥品的壟斷權)
    • 補助金、稅額扣抵
  • 課題
    • 罕見疾病用醫藥品的成本高
    • 病歷的認識和臨床實驗參加者的不足
    • 跟學名藥產業的競爭激烈

第5章 全球罕見疾病用醫藥品市場:概要

第6章 市場明細

  • 各類型
  • 各地區
  • 各用途

第7章 罕見疾病用醫藥品的開發中產品現況

第8章 市場趨勢與發展

  • 腫瘤罕見疾病用醫藥品的數量增加
  • 遺傳基因療法:罕見疾病的治療方法大受歡迎

第9章 企業合併、收購 (M&A)

第10章 法規方案

  • 美國
  • 歐洲
  • 日本
  • 印度
  • 中國

第11章 競爭環境

第12章 主要企業分析

  • Novartis
  • F. Hoffmann-La Roche AG
  • Celgene Corporation
  • Pfizer Inc.
  • Sanofi
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Boehringer Ingelheim GmbH
  • AbbVie

第13章 機會及建議

  • 市場機會
  • 建議

圖表一覽

目錄

Orphan drugs, also called niche busters, are intended to treat patients suffering from very serious diseases for which no treatment or at least a satisfactory one, has so far been available. These diseases, often referred to as orphan diseases or rare diseases, affect only a small portion of the population. The number of diseases for which no treatment is currently available is estimated to be between 4,000 to 5,000, worldwide. The patent expiry of blockbuster drugs and increased competition from generics has shifted the focus of pharmaceutical industry from the essential medicines to orphan drugs. Incentives for drug development provided by governments, as well as support from the regulatory bodies, are a further boost for the companies developing orphan drugs all over the world.

According to the report “Global Orphan Drugs Market Outlook 2020”, the orphan drug market is anticipated to reach around US$ 180 Billion by 2020. The report provides a detailed analysis of the market for these orphan drugs. An estimation of the market potential of these drugs has been done keeping in mind that many more of these drugs are being tested in clinical trials for various indications, apart from the ones that are already approved. Furthermore, the report also provides the revenue generated by top 10 orphan drugs in 2014.

The report provides information about the segments of the orphan drug market on the basis of type, geography, and therapeutic application. It also highlights orphan drugs at various stages of clinical development. In addition, the report also provides insight about the major drivers and challenges, latest trends and developments, and strategic collaborations impacting the industry growth. The regulatory scenario of orphan drug industry across different geographic regions of the world has also been discussed in the report.

The later part of the report discusses some of the prominent players in the global orphan drug market. A brief business overview of each player has been provided along with their business segments, product portfolios, and recent developments. Moreover, analysis of their strengths and weaknesses has also been done. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.

Table of Contents

1. Analyst View

2. Research Methodology

3. Orphan Drug - An Introduction

4. Drivers and Challenges

  • 4.1. Drivers
    • 4.1.1. Rising Healthcare Expenditure
    • 4.1.2. Increasing Prevalence of Chronic Diseases
    • 4.1.3. Shorter Development Timeline & Orphan Drug Exclusivity (ODE)
    • 4.1.4. Grants and Tax Credits
  • 4.2. Challenges
    • 4.2.1. High Cost of Orphan Drugs
    • 4.2.2. Lack of Disease History Awareness & Research Participants
    • 4.2.3. Increased Competition from Generics Industry

5. Global Orphan Drug Market - Overview

6. Market Segmentation

  • 6.1. By Type
  • 6.2. By Geography
  • 6.3. By Applications

7. Current Status of Orphan Drugs in Pipeline

8. Trends and Developments

  • 8.1. Rise in Number of Orphan Drugs for Oncology
  • 8.2. Gene Therapy- Gaining Popularity for Rare Conditions

9. Mergers and Acquisitions

10. Regulatory Scenario

  • 10.1. US
  • 10.2. EU
  • 10.3. Japan
  • 10.4. India
  • 10.5. China

11. Competitive Landscape

12. Key Player Analysis

  • 12.1. Novartis
  • 12.2. F. Hoffmann-La Roche AG
  • 12.3. Celgene Corporation
  • 12.4. Pfizer Inc.
  • 12.5. Sanofi
  • 12.6. Bristol-Myers Squibb
  • 12.7. Johnson & Johnson
  • 12.8. Merck & Co., Inc.
  • 12.9. Boehringer Ingelheim GmbH
  • 12.10. AbbVie

13. Opportunities & Recommendations

  • 13.1. Opportunities
  • 13.2. Recommendations

List of Figures:

  • Figure 5-1: Global - Orphan Drugs Market (Billion US$), 2014-2020
  • Figure 6-1: Global - Orphan Drugs Market by Type (%), 2014
  • Figure 6-2: Global - Orphan Drugs Market by Geography (%), 2014
  • Figure 6-3: Global - Orphan Drugs Market by Applications (%), 2014
  • Figure 11-1: Share of Major Players in Orphan Drugs Market (%), 2014
  • Figure 12-1: Novartis - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-2: Roche - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-3: Celgene Corporation - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-4: Pfizer Inc - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-5: Sanofi - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-6: Bristol Myers Squibb - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-7: Johnson & Johnson - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-8: Merck & Co., Inc. - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-9: Boehringer Ingelheim GmbH - Break up of Revenue by Geographies (%), 2014
  • Figure 12-10: AbbVie - Break up of Revenue by Geographies (%), 2014

List of Tables:

  • Table 7-1: Major Orphan Drugs Pipeline
  • Table 9-1: Major Consolidations in Orphan Drug Market (2014-2015)
  • Table 11-1: Global - Major Orphan Drugs Revenue (Billion US$), 2014
  • Table 12-1: Novartis - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-2: Novartis - Orphan Drugs
  • Table 12-3: Roche - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-4: Roche - Orphan Drugs
  • Table 12-5: Celgene Corporation - Orphan Drugs
  • Table 12-6: Pfizer Inc - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 12-7: Pfizer Inc - Orphan Drugs
  • Table 12-8: Sanofi - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-9: Sanofi - Orphan Drugs
  • Table 12-10: Bristol Myers Squibb - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-11: Bristol Myers Squibb - Orphan Drugs
  • Table 12-12: Johnson & Johnson - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-13: Johnson & Johnson - Orphan Drugs
  • Table 12-14: Merck & Co., Inc. - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-15: Merck & Co., Inc. - Orphan Drugs
  • Table 12-16: Boehringer Ingelheim GmbH - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 12-17: Boehringer Ingelheim GmbH - Orphan Drugs
  • Table 12-18: AbbVie - Orphan Drugs
Back to Top